IGF-I/IGFBP-3 ratio: A mechanistic insight into the metabolic syndrome

Clinical Science

Volumn 116, Issue 6, 2009, Pages 507-512

  Sierra Johnson, Justo ^a   Romero Corral, Abel ^b   Somers, Virend K ^b   Lopez Jimenez, Francisco ^b   Mälarstig, Anders ^a   Brismar, Kerstin ^c   Hamsten, Anders ^a   Fisher, Rachel M ^a   Hellénius, Mai Lis ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAYO CLINIC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cardiovascular disease; Insulin resistance; Insulin like growth factor binding protein 3 (IGFBP 3); Insulin like growth factor I (IGF I); Metabolic syndrome; Third National Health and Nutrition Examination Survey (NHANES III)

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRIACYLGLYCEROL; BIOLOGICAL MARKER; IGFBP3 PROTEIN, HUMAN; SOMATOMEDIN BINDING PROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GENE FUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RACE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CROSS-SECTIONAL STUDY; MIDDLE AGED; PHYSIOLOGY; STATISTICAL MODEL;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MODELS, STATISTICAL; YOUNG ADULT;

EID: 65549106138     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080382     Document Type: Article

References (30)

1. Laughlin, G. A., Barrett-Connor, E., Criqui, M. H. and Kritz-Silverstein, D. (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGFbinding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 89, 114-120
2. Juul, A., Scheike, T., Davidsen, M., Gyllenborg, J. and Jørgensen, T. (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106, 939-944
3. Vasan, R. S., Sullivan, L. M., D'Agostino, R. B. et al. (2003) Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann. Intern. Med. 139, 642-648
4. Conti, E., Carrozza, C., Capoluongo, E. et al. (2004) Insulin-like growth factor-1 as a vascular protective factor. Circulation 110, 2260-2265
5. Fowlkes, J. L., Serra, D. M., Bunn, R. C., Thrailkill, K. M., Enghild, J. J. and Nagase, H. (2004) Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexes. Endocrinology 145, 620-626
6. Wallander, M., Brismar, K., Ohrvik, J., Rydén, L. and Norhammar, A. (2006) Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia 49, 2247-2255
7. Ezzat, V. A., Duncan, E. R., Wheatcroft, S. B. and Kearney, M. T. (2008) The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 10, 198-211
8. Lopez-Bermejo, A., Khosravi, J., Fernandez-Real, J. M. et al. (2006) Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25). Diabetes 55, 2333-2339
9. Jeschke, M. G., Bolder, U., Chung, D. H. et al. (2007) Gut mucosal homeostasis and cellular mediators after severe thermal trauma and the effect of insulin-like growth factor-I in combination with insulin-like growth factor binding protein-3. Endocrinology 148, 354-362
10. Bayes-Genis, A., Conover, C. A. and Schwartz, R. S. (2000) The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ. Res. 86, 125-130
11. Janssen, J. A. and Lamberts, S.W. (2002) The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur. J. Endocrinol. 146, 467-477
12. Clauson, P. G., Brismar, K., Hall, K., Linnarsson, R. and Grill, V. (1998) Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand. J. Clin. Lab. Invest. 58, 353-360
13. Lee, P. D., Giudice, L. C., Conover, C. A. and Powell, D. R. (1997) Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med. 216, 319-357
14. Kaplan, R. C., McGinn, A. P., Pollak, M. N. et al. (2007) Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J. Clin. Endocrinol. Metab. 92, 1319-1325
15. Wallander, M., Norhammar, A., Malmberg, K., Ohrvik, J., Rydén, L. and Brismar, K. (2007) Insulin-like growth factor binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care 30, 2343-2348
16. Boquist, S., Ruotolo, G., Skoglund-Andersson, C. et al. (2008) Correlation of serum IGF-I and IGFBP-1 and -3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin. Endocrinol. 68, 51-58
17. Muzumdar, R. H., Ma, X., Fishman, S. et al. (2006) Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes 55, 2788-2796
18. Sierra-Johnson, J. Somers, V. K., Kuniyoshi, F. H. et al. (2006) Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am. J. Cardiol. 98, 1369-1373
19. Berrigan, D., Potischman, N., Dodd, K. W. et al. (2007) Serum levels of insulin-like growth factor-I and insulinlike growth factor-I binding protein-3: quality control for studies of stored serum. Cancer Epidemiol. Biomarkers Prev. 16, 1017-1022
20. Grundy, S. M., Cleeman, J. I., Daniels, S. R. et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752
21. DeLong, E. R., DeLong, D. M. and Clarke-Pearson, D. L. (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837-845
22. Frystyk, J. (2004) Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 14, 337-375
23. Davis, M. E., Hsieh, P. C., Takahashi, T. et al. (2006) Local myocardial insulin-like growth factor 1 delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl. Acad. Sci. U.S.A. 103, 8155-8160
24. Wang, P. H. (2001) Roads to survival: insulin-like growth factor-1 signaling pathways in cardiac muscle. Circ. Res. 88, 552-554
25. Johansson, G. S. and Arnqvist, H. J. (2006) Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am. J. Physiol. Endocrinol. Metab. 291, E1124-E1130
26. Akanji, A. O., Suresh, C. G. and Al-Radwan, R. (2007) Insulin-like growth factor (IGF)-I, IGF-II and IGFbinding protein (IGFBP)-3 levels in Arab subjects with coronary heart disease. Scand. J. Clin. Lab. Invest. 67, 553-559
27. Saydah, S., Graubard, B., Ballard-Barbash, R. and Berrigan, D. (2007) Insulin-like growth factors and subsequent risk of mortality in the United States. Am. J. Epidemiol. 166, 518-526
28. Chan, S. S., Twigg, S.M., Firth, S. M. and Baxter, R. C. (2005) Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J. Clin. Endocrinol. Metab. 90, 6588-6595
29. Kaushal, K., Heald, A. H. and Siddals, K. W. (2004) The impact of abnormalities in IGF and inflammatory systems on the metabolic syndrome. Diabetes Care 27, 2682-2688
30. McDonald, A., Williams, R. M., Regan, F. M., Semple, R. K. and Dunger, D. B. (2007) IGF-I treatment of insulin resistance. Eur. J. Endocrinol. 157 (Suppl. 1), S51-S56